China Biologic Products (NASDAQ:CBPO) Upgraded by Zacks Investment Research to Hold

China Biologic Products (NASDAQ:CBPO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday, February 5th.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

Separately, BidaskClub raised shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $137.50.

Shares of China Biologic Products (NASDAQ CBPO) traded up $0.85 during trading on Monday, reaching $79.95. 137,187 shares of the company’s stock traded hands, compared to its average volume of 196,369. The stock has a market capitalization of $2,620.61, a PE ratio of 17.62, a PEG ratio of 1.00 and a beta of 1.67. China Biologic Products has a twelve month low of $72.21 and a twelve month high of $120.46.

Several hedge funds have recently made changes to their positions in CBPO. Schroder Investment Management Group grew its stake in shares of China Biologic Products by 86.5% in the third quarter. Schroder Investment Management Group now owns 1,016,092 shares of the biopharmaceutical company’s stock worth $92,799,000 after acquiring an additional 471,416 shares during the period. Comgest Global Investors S.A.S. grew its stake in shares of China Biologic Products by 78.5% in the fourth quarter. Comgest Global Investors S.A.S. now owns 635,752 shares of the biopharmaceutical company’s stock worth $50,078,000 after acquiring an additional 279,500 shares during the period. Artisan Partners Limited Partnership grew its stake in shares of China Biologic Products by 62.9% in the third quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock worth $66,790,000 after acquiring an additional 279,420 shares during the period. New Silk Road Investment PTE Ltd. bought a new stake in shares of China Biologic Products in the third quarter worth approximately $17,476,000. Finally, Bank of New York Mellon Corp grew its stake in shares of China Biologic Products by 30.1% in the third quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock worth $70,380,000 after acquiring an additional 176,325 shares during the period. Hedge funds and other institutional investors own 52.44% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/12/china-biologic-products-cbpo-upgraded-to-hold-at-zacks-investment-research.html.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply